OxFORD Asset Management LLP lessened its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 30.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 134,002 shares of the biopharmaceutical company’s stock after selling 59,866 shares during the quarter. OxFORD Asset Management LLP owned about 0.28% of Cytokinetics, worth $1,621,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the stock. FMR LLC raised its stake in Cytokinetics, by 8.8% in the first quarter. FMR LLC now owns 5,655,916 shares of the biopharmaceutical company’s stock valued at $72,679,000 after purchasing an additional 456,502 shares in the last quarter. Vanguard Group Inc. raised its stake in Cytokinetics, by 59.9% in the second quarter. Vanguard Group Inc. now owns 3,117,496 shares of the biopharmaceutical company’s stock valued at $37,721,000 after purchasing an additional 1,168,151 shares in the last quarter. Citigroup Inc. raised its stake in Cytokinetics, by 9.9% in the second quarter. Citigroup Inc. now owns 800,471 shares of the biopharmaceutical company’s stock valued at $9,686,000 after purchasing an additional 71,811 shares in the last quarter. Acadian Asset Management LLC raised its stake in Cytokinetics, by 128.9% in the second quarter. Acadian Asset Management LLC now owns 766,263 shares of the biopharmaceutical company’s stock valued at $9,271,000 after purchasing an additional 431,457 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Cytokinetics, by 252.0% in the second quarter. Bank of New York Mellon Corp now owns 526,790 shares of the biopharmaceutical company’s stock valued at $6,374,000 after purchasing an additional 377,145 shares in the last quarter. 71.50% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “OxFORD Asset Management LLP Has $1.62 Million Position in Cytokinetics, Incorporated (CYTK)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/10/oxford-asset-management-llp-has-1-62-million-position-in-cytokinetics-incorporated-cytk.html.

In related news, SVP Bradley Paul Morgan sold 118,330 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $15.00, for a total transaction of $1,774,950.00. Following the transaction, the senior vice president now directly owns 63,107 shares of the company’s stock, valued at approximately $946,605. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Robert I. Blum sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $13.79, for a total value of $68,950.00. Following the transaction, the chief executive officer now directly owns 84,785 shares in the company, valued at $1,169,185.15. The disclosure for this sale can be found here. Over the last three months, insiders have sold 164,809 shares of company stock worth $2,424,822. 7.20% of the stock is currently owned by insiders.

CYTK has been the subject of a number of analyst reports. Zacks Investment Research raised Cytokinetics, from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Tuesday, July 11th. BidaskClub raised Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Morgan Stanley started coverage on Cytokinetics, in a research note on Monday, July 31st. They set an “overweight” rating and a $24.00 target price for the company. HC Wainwright set a $26.00 target price on Cytokinetics, and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Cowen and Company reissued a “buy” rating and set a $19.00 target price on shares of Cytokinetics, in a research note on Friday, August 4th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Cytokinetics, has an average rating of “Buy” and a consensus price target of $21.64.

Cytokinetics, Incorporated (NASDAQ:CYTK) opened at 15.40 on Tuesday. Cytokinetics, Incorporated has a 52 week low of $8.77 and a 52 week high of $17.20. The firm’s market cap is $826.46 million. The firm’s 50-day moving average price is $14.27 and its 200 day moving average price is $13.80.

Cytokinetics, (NASDAQ:CYTK) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.03). The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $5.28 million. Cytokinetics, had a negative net margin of 16.00% and a negative return on equity of 14.15%. Equities analysts forecast that Cytokinetics, Incorporated will post ($2.51) earnings per share for the current fiscal year.

About Cytokinetics,

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Institutional Ownership by Quarter for Cytokinetics, (NASDAQ:CYTK)

Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.